On Nov. 18, 2026, Recursion shares climbed after regulators aligned on its lead familial adenomatous polyposis trial, though investors are watching for more detail.
| Quartal / Datum | EPS (USD) | Schätzung (USD) | Abweichung |
|---|
| Quartal / Datum | Umsatz (Mio USD) | Schätzung (Mio USD) | Abweichung |
|---|